#3-79E. Unlocking the Genome: The Triumphs and Trials of GWAS (Nat Rev Genet, 2019)

How does personalized medicine based on genetic information impact our daily clinical practice and patient outcomes? In today's episode, we delve into the paper "Benefits and limitations of genome-wide association studies," a comprehensive review that evaluates the monumental achievements and ongoing challenges of GWAS in elucidating the genetic architectures of complex human diseases. The study's most crucial clinical takeaway highlights the growing applicability of GWAS findings, such as using polygenic risk scores for clinical disease risk stratification and identifying novel therapeutic targets for early drug discovery. However, when critically appraising this evidence, it is essential to consider the inherent limitations of standard single-nucleotide polymorphism arrays, particularly their inability to detect ultra-rare mutations and their currently modest predictive value for individual disease onset. For physicians, grasping these nuances is vital to comprehensively understanding the current landscape and future trajectory of precision medicine, ultimately guiding more informed, genotype-based therapeutic optimizations and patient stratification strategies in your everyday clinical practice.

Citation: Tam V, Meyre D. Benefits and limitations of genome-wide association studies. Nature Reviews Genetics. 2019. DOI: 10.1038/s41576-019-0127-1

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.